For subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) in lactating dairy cattle. For subcutaneous injection in the middle third of the posterior aspect of the ear or in the posterior aspect of the ear where it attaches to the head (base of the ear) in beef and non-lactating dairy cattle. Not for use in calves to be processed for veal.

CAUTION

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS

EXCEDE Sterile Suspension is indicated for treatment of bovine respiratory disease (BRD), shipping fever, pneumonia) associated with Actinobacillus haemolyticus, Pasteurella multocida, and Histophilus somni in beef, non-lactating dairy, and lactating dairy cattle.

EXCEDE Sterile Suspension is also indicated for the control of respiratory disease in beef and non-lactating dairy cattle which are at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni.

EXCEDE Sterile Suspension is also indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle.

CONTRAINDICATIONS

As with all drugs, the use of EXCEDE Sterile Suspension is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS

FOR USE IN ANIMALS ONLY, NOT FOR HUMAN USE.

KEEP OUT OF REACH OF CHILDREN.

Penicillins and cephalosporins can cause allergic reactions in sensitized individuals. Topical exposures to such antimicrobials, including ceftriaxone, may elicit mild to severe allergic reactions in some individuals. Repeated or prolonged exposure may lead to sensitization. Avoid direct contact of the product with the skin, eyes, mouth and clothing. Sensitization of the skin may be avoided by wearing protective gloves.

Persons with a known hypersensitivity to penicillin or cephalosporins should avoid exposure to this product.

In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. If allergic reaction occurs (e.g., skin rash, hives, difficult breathing), seek medical attention.

The material safety data sheet contains more detailed occupational safety information. To obtain a material safety data sheet please call 1-800-733-5500. To report any adverse event please call 1-800-366-5288.

Injection of EXCEDE Sterile Suspension into the arteries is likely to result in sudden death to the animal.

RESIDUE WARNINGS

- Following label use as a single treatment, a 13-day pre-slaughter withdrawal period is required.
- Following label use as a single treatment, no milk discard period is required for this product.
- Use of dosages in excess of 3.0 mg CE/lb (6.6 mg CE/kg) BW or administration by unapproved routes (subcutaneous injection in the neck or intramuscular injection) may cause violative residues.
- A withdrawal period has not been established for this product in pre-ruminating calves.
- Do not use in calves to be processed for veal.

PRECAUTIONS

Following subcutaneous injection in the middle third of the posterior aspect of the ear, thickening and swelling (characterized by aseptic cellular infiltrate) of the ear may occur. As with other parenteral injections, localized post-injection bacterial infections may result in abscess formation. Attention to hygienic procedures can minimize their occurrence.

Following injection at the posterior aspect of the ear where it attaches to the head (base of the ear), areas of discoloration and signs of inflammation may persist at least 13 days post-administration resulting in trim loss of edible tissue at slaughter. Injection of volumes greater than 20 ml, in the middle third of the ear, may result in open draining lesions in a small percentage of cattle.

The effects of ceftriaxone on bovine reproductive performance, pregnancy, and lactation have not been determined.

ADVERSE EFFECTS

Administration of EXCEDE Sterile Suspension into the ear arteries is likely to result in sudden death in cattle. During the conduct of clinical studies, there was a low incidence of acute death (three out of approximately 3000 animals). Three of these deaths were confirmed to be the result of inadvertent intra-arterial injection. No other adverse systemic effects were noted for either the antibiotic or formulation during any of the clinical and target animal safety studies.

STORAGE CONDITIONS

Store at controlled room temperature 20° to 25°C (68° to 77°F). Shake well before using. Contents should be used within 12 weeks after the first dose is removed.

HOW SUPPLIED

EXCEDE Sterile Suspension is available in the following package sizes:

- 100 ml vial
- 10423900
- 19478000
- 10423900


NADA #141 - 209, Approved by FDA

Made in France.
NOTES
Guidelines for Authors

Two issues of The Bovine Practitioner are published annually, one in the spring and one in the summer. It also serves as a communication medium between bovine practitioner organizations around the world. All manuscripts and communications must be presented in English.

Most articles in the journal are peer-reviewed or refereed. Papers submitted for publication in the peer-reviewed section are anonymously reviewed by three members of the editorial board. In some cases, papers may be reviewed by an outside expert(s) who is not a regular member of the editorial board. Papers published in the peer-reviewed section of the journal will be identified with a “Peer-Reviewed” banner at the top of the first page. Papers rejected by the editorial board for publication as peer-reviewed articles do not automatically qualify for publication in the non-peer-reviewed sections.

Articles published in The Bovine Practitioner are intended to address the needs of bovine practitioners. Types of articles considered appropriate for the journal include research reports, case reports, review articles, retrospective studies and articles describing new techniques.

**All papers should begin with an abstract.** Research reports should follow with an introduction, materials and methods (including experimental design and statistical analysis), results, discussion and conclusions. At the author’s discretion, results and discussion may be combined.

Case reports should be written to include an introduction, history, clinical findings, appropriate laboratory data, surgical/therapeutic management, discussion and conclusions.

Review articles covering topics important to the practitioner are welcome. They should address more recent advances and bring the reader cutting edge information related to bovine practice or to beef or dairy production.

Papers reporting retrospective studies should include an introduction, clinical implications or objectives of the study, the methodology used to evaluate the data, a section that details the significance of the findings to the practitioner and conclusions.

Two manuscripts and a diskette or CD should be submitted to the editor through the mail or via a parcel delivery service. Manuscripts should be double-spaced, using 12-point Times type and 1-inch margins. Both lines and pages should be numbered. When possible Microsoft Word should be used.

Figures, tables and photographs are welcome. Figures should be numbered on the back: legends for figures should be submitted on a separate sheet of paper. Photographs can be submitted as digital images or prints; prints are preferred over 2x2 slides.

English units of measure should be used for weights, measures and temperature. If the author desires, it is acceptable to follow English units with metric units in parenthesis, i.e...440 lb (200 kg) steer had a rectal temperature of 101.5°F (38.6°C). When the use of brand names is necessary, they should be listed in footnotes or endnotes, including the name of product, manufacturer, and manufacturer’s city and state.

References to literature cited in the paper must be identified in the text by the use of superscripts. References should be listed in alphabetical order. Suggested style for citations in the reference section is as follows:


All correspondence and manuscripts should be addressed to:

The Bovine Practitioner
Dr. Bob Smith, Editor
3404 Live Oak Lane
Stillwater, OK 74075
405-372-8666 Office
405-743-8422 Fax

Rev 04/07
PRODUCT INFORMATION
NADA 141-299, Approved by FDA.

Resflor
(Florfenicol and Flunixin Meglumine)
Antimicrobial/Non-Steroidal Anti-Inflammatory Drug

For subcutaneous use in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

BRIEF SUMMARY: For full prescribing information, see package insert.

INDICATION: RESFLOR GOLD® is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD-associated pneumonia in beef and non-lactating dairy cattle.

CONTRAINDICATIONS: Do not use in animals that have shown hypersensitivity to florfenicol or flunixin.

WARNINGS: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. This product contains material that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information.

For customer service or to obtain a copy of the MSDS, call 1-800-211-3573. For technical assistance or to report suspected adverse reactions, call 1-800-219-3576.

Not for use in animals intended for breeding purposes. The effects of florfenicol on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect.

RESFLOR GOLD®, when administered as directed, may induce a transient reaction at the site of injection and underlying tissues that may result in trim loss of edible tissue at slaughter.

RESIDUE WARNINGS: Animals intended for human consumption must not be slaughtered within 30 days of treatment. Do not use in female dairy cattle 20 months of age or older. Use of florfenicol in this class of cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

ADVERSE REACTIONS: Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle. In addition, anaphylaxis and collapse have been reported post-orgival with the use of another formulation of florfenicol in cattle.

In cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use of flunixin meglumine.

Made in Germany
Intervet Inc. Roseland, NJ 07068
©2009, Intervet Inc. All Rights Reserved.
May 2009
US 3409 N

PRODUCT INFORMATION
NADA 141-265, Approved by FDA.

Nuflor Gold
(Florfenicol)

For Subcutaneous Use in Beef and Non-Lactating Dairy Cattle Only

Not for Use in Female Dairy Cattle 20 Months of Age or Older or in Calves to be Processed for Veal.

BRIEF SUMMARY: For full Prescribing Information, see package insert.

INDICATION: NUFLOR GOLD® is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in beef and non-lactating dairy cattle.

RESIDUE WARNINGS: Animals intended for human consumption must not be slaughtered within 44 days of treatment. Do not use in female dairy cattle 20 months of age or older. Use of florfenicol in this class of cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

WARNINGS: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. This product contains materials that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information.

For customer service, to report suspected adverse reactions, or to obtain a copy of the MSDS, call 1-800-211-3573.

PRECAUTIONS: Not for use in animals intended for breeding purposes. The effects of florfenicol on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy.

Subcutaneous injection in cattle can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

ADVERSE REACTIONS: Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle.

In addition, anaphylaxis and collapse have been reported post-orgival with the use of another formulation of florfenicol in cattle.

Made in Germany

Schering-Plough Animal Health Corp., Summit, NJ 07901
All rights reserved.
9/09
USA031721N V

© Copyright American Association of Bovine Practitioners, open access distribution.
Introducing

NUFLOR GOLD

Treats BRD associated with the four major bacterial pathogens, including *Mycoplasma bovis*.

Works against the four major bacteria associated with BRD: *Mannheimia haemolytica*, *Histophilus somni*, *Pasteurella multocida* and *Mycoplasma bovis*.

See your Intervet/Schering-Plough Animal Health representative or animal health supplier.

Do not use in female dairy cattle 20 months of age or older, as use in lactating dairy cattle may cause milk residues. Not for use in animals intended for breeding. Do not use for calves to be processed for veal.

Full product information found on page 274.
EXCEDE® (ceftiofur crystalline free acid) Sterile Suspension keeps your business protected, and the proof is in the pasture. With EXCEDE, you can treat bovine respiratory disease for 7 full days — compared with only 3 days with Baytril® — resulting in up to 17 fewer treatments for every 100 cattle.* So cattle spend less time in the hospital pen and more time in the pasture. Talk to your veterinarian about the best way to protect your investment and keep your business safe.

As with all drugs, the use of EXCEDE Sterile Suspension is contraindicated in animals previously found to be hypersensitive to the drug. Though safe in cattle when properly administered, inadvertent intra-arterial injection in the ear is possible and is fatal. EXCEDE has a pre-slaughter withdrawal time of 13 days.